Ambra Pozzi Archives
VUMC study raises hope for improving treatment of kidney disease
Feb. 2, 2022—Vanderbilt research has revealed an important mechanism in the kidney by which a cell surface receptor known as DDR1 fans the flames of inflammation and fibrosis that ultimately lead to kidney failure.
Pozzi elected president of Society for Matrix Biology
Jan. 20, 2022—Vanderbilt's Ambra Pozzi, PhD, has been elected president of the American Society for Matrix Biology (ASMB), a scientific organization that promotes research on the extracellular matrix with the aim of improving human health.
New way to bEET insulin resistance
Nov. 11, 2021—Signaling molecules called EETs could improve insulin resistance, a primary risk factor for Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.
Protein study may be key to treating fibrotic diseases
Jul. 30, 2020—A protein linked to amyotrophic lateral sclerosis (ALS), a progressive neurological disease that causes muscle weakness, may be a key to treating fibrotic disease of the kidneys and other organs, researchers at Vanderbilt University Medical Center reported recently.
New window on fibrosis
Aug. 8, 2019—A previously unrecognized role for a cell surface receptor may open new therapeutic options for the treatment of fibrotic diseases.
Major grant to enhance kidney disease research
Sep. 28, 2017—Vanderbilt’s Division of Nephrology and Hypertension has received a five-year, $5 million federal grant to provide core research services in the fight against kidney disease.
EETs contribute to insulin sensitivity
May. 11, 2017—Interventions that increase circulating levels of compounds called EETs may improve insulin sensitivity and treat hypertension.
Surprising finding by VU team sheds light on fibrotic disease
Jan. 19, 2017—Integrins are membrane proteins made up of combinations of different “alpha” and “beta” subunits that enable cells throughout the body to interact with their surroundings.
Molecular ‘chat’ holds kidney fibrosis clues
Jul. 10, 2014—A novel molecular “conversation” regulates kidney fibrosis – the final result of end-stage chronic kidney disease – suggesting new treatment options for this currently irreversible process.
New center dedicated to kidney disease
May. 29, 2014—Kidney disease is the eighth most common cause of death in the United States and affects more than 20 million people, yet many people don’t know they have kidney disease because it often develops very slowly and with minimal symptoms. For this reason, kidney disease is often referred to as a silent killer.
New direction for treating lung cancer
Feb. 7, 2014—Targeting the production of molecules that promote tumor blood vessel development offers a new path for treating lung cancer.
